These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 32150328)

  • 21. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.
    Wang C; Shen D; Yuan L; Dong Q; Xu S; Liu Y; Xiao J
    Quant Imaging Med Surg; 2024 Feb; 14(2):2021-2033. PubMed ID: 38415121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
    Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
    Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
    Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy.
    Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU
    Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy.
    Nyarangi-Dix J; Wiesenfarth M; Bonekamp D; Hitthaler B; Schütz V; Dieffenbacher S; Mueller-Wolf M; Roth W; Stenzinger A; Duensing S; Roethke M; Teber D; Schlemmer HP; Hohenfellner M; Radtke JP
    Eur Urol Focus; 2020 Nov; 6(6):1205-1212. PubMed ID: 30477971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy.
    Castellani D; Cecchini S; Mazzucchelli R; Soraci L; Di Rosa M; Fabbietti P; Palagonia E; Puccio F; Carnevali F; Paci E; Montironi R; Galosi AB
    Urol Oncol; 2022 Aug; 40(8):379.e1-379.e8. PubMed ID: 35662497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and External Validation of a Novel Nomogram to Predict Side-specific Extraprostatic Extension in Patients with Prostate Cancer Undergoing Radical Prostatectomy.
    Soeterik TFW; van Melick HHE; Dijksman LM; Küsters-Vandevelde H; Stomps S; Schoots IG; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2022 Jun; 5(3):328-337. PubMed ID: 32972895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.
    Venderbos LD; Roobol MJ; Bangma CH; van den Bergh RC; Bokhorst LP; Nieboer D; Godtman R; Hugosson J; van der Kwast T; Steyerberg EW
    World J Urol; 2016 Feb; 34(2):253-60. PubMed ID: 26160006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
    Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
    Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
    Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
    Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
    Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
    J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The additional value of
    Heetman JG; Paulino Pereira LJ; Kelder JC; Soeterik TFW; Wever L; Lavalaye J; van der Hoeven EJRJ; Lam MGEH; van Melick HHE; van den Bergh RCN
    Prostate; 2024 Aug; 84(11):1025-1032. PubMed ID: 38704755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
    Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
    Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
    Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.
    Yilmaz EC; Lin Y; Belue MJ; Harmon SA; Phelps TE; Merriman KM; Hazen LA; Garcia C; Johnson L; Lay NS; Toubaji A; Merino MJ; Patel KR; Parnes HL; Law YM; Wood BJ; Gurram S; Choyke PL; Pinto PA; Turkbey B
    AJR Am J Roentgenol; 2024 Jan; 222(1):e2329964. PubMed ID: 37729551
    [No Abstract]   [Full Text] [Related]  

  • 38. How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
    Gandaglia G; van den Bergh RCN; Tilki D; Fossati N; Ost P; Surcel CI; Sooriakumaran P; Tsaur I; Valerio M; Kretschmer A; Zaffuto E; Salomon L; Montorsi F; Graefen M; van der Poel H; de la Taille A; Briganti A; Ploussard G;
    BJU Int; 2018 Nov; 122(5):823-830. PubMed ID: 29772103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI-based PI-RADS score predicts ISUP upgrading and adverse pathology at radical prostatectomy in men with biopsy ISUP 1 prostate cancer.
    Dekalo S; Mazliah O; Barkai E; Bar-Yosef Y; Herzberg H; Bashi T; Fahoum I; Barnes S; Sofer M; Yossepowitch O; Keren-Paz G; Mano R
    Can J Urol; 2024 Aug; 31(4):11955-11962. PubMed ID: 39217520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis.
    Leong JY; Herrera-Caceres JO; Goldberg H; Tham E; Teplitsky S; Gomella LG; Trabulsi EJ; Lallas CD; Fleshner NE; Tilki D; Chandrasekar T
    Urology; 2020 Mar; 137():102-107. PubMed ID: 31705947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.